Hosted on MSN3h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
The Trump administration ordered an immediate pause on public communications from federal health agencies like the CDC, FDA, ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback